Many of the larger pharmaceutical companies are either experiencing sagging sales from the onset of generic competition or are facing a bleak future with no compounds in their pipelines to account for upcoming patent expirations on their top drugs. Schering-Plough
For the year, Schering's sales, adjusted to account for half of the revenue from the Merck
Speaking of R&D, although Schering doesn't have the largest pipeline in the world, it can claim a few notable compounds, including its phase 2 protease inhibitor for hepatitis C, and there's also the possibility for label-expanding indications on Remicade and the Zetia/Vytorin franchise, which together represented nearly a fourth ($3.2 billion) of Schering's total revenue and experienced sales growth of almost 50% last year.
Without solid financials, any pharmaceutical firm's R&D is going to suffer, and without a strong pipeline, its financials are bound to hit a wall at some point. Considering that Schering-Plough is strong in both areas and is trading at 23 times analyst estimates of $1.07 for next year's earnings, investors would be smart to take a look at this pharmaceutical turnaround stock before it starts to get noticed again.